1-10 of 10
Louise Stanton
Close
Sort by
Journal Articles

Does R-IPI Remain Predictive of Relapse Risk for Patients with DLBCL Achieving a Complete Remission with Frontline Therapy: Landmark Analysis of Two Large Prospective Clinical Trials

Dima El-Sharkawi, Tasneem Elnafie, Sarah Thompson, Louise Stanton, Nicholas Counsell, Amit Sud, Ian Chau, Bhupinder Sharma, Peter Johnson, David C. Linch, Sunil Iyengar, Andrew Davies, David Cunningham
Journal: Blood
Blood (2022) 140 (Supplement 1): 7908–7909.
https://doi.org/10.1182/blood-2022-167852
Published: 2022
Journal Articles

Quality of Life Trajectories in Patients Treated with R-CHOP for Diffuse Large B-Cell Lymphoma As Part of the Remodl-B Trial (ISRCTN 51837425)

Joanna Hack, Inês Ralha, Sam Wilding, Louise Stanton, Josh Caddy, Sharon Barrans, Christoph Mamot, Urban Novak, Cathy Burton, Pamela McKay, Gavin Campbell, Andrew Davies, Peter Johnson
Journal: Blood
Blood (2022) 140 (Supplement 1): 6648–6649.
https://doi.org/10.1182/blood-2022-159442
Published: 2022
Journal Articles

Durable Responses from Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study

Andrew J Davies, Josh Caddy, Katy McLaughlin, Christopher Wignall, Robert Waugh, Graham P. Collins, Louise Stanton, Geoff N Saunders, Thomas Cummin, Anna Schuh, Kirit M. Ardeshna, Andrew K. McMillan, John Radford, David John Lewis, Adam R Coleman, Gareth Griffiths, Cathy Burton, Sharon Barrans, Peter Johnson
Journal: Blood
Blood (2022) 140 (Supplement 1): 9478–9479.
https://doi.org/10.1182/blood-2022-163499
Published: 2022
Journal Articles

Five-Year Survival Results from the Remodl-B Trial (ISRCTN 51837425) Show Improved Outcomes in Diffuse Large B-Cell Lymphoma Molecular Subgroups from the Addition of Bortezomib to R-CHOP Chemoimmunotherapy

Andrew J Davies, Louise Stanton, Josh Caddy, Sharon Barrans, Sam Wilding, Geoff N Saunders, Christoph Mamot, Urban Novak, Andrew K. McMillan, Paul A Fields, Graham P. Collins, Richard Stephens, Francesco Cucco, Chulin Sha, Moniek Van Hoppe, Reuben M Tooze, Matthew A Care, Gareth Griffiths, Anna Schuh, Ming-Qing Du, David R Westhead, Cathy Burton, Peter Johnson
Journal: Blood
Blood (2022) 140 (Supplement 1): 1770–1772.
https://doi.org/10.1182/blood-2022-159976
Published: 2022
Journal Articles

Clinical and Biological Effects of Combined CD27 and CD20 Antibody Therapy in Relapsed/Refractory B-Cell Lymphoma: The Riva Trial

Sean H Lim, Heng Sheng Sow, Christopher Wignall, Katy Mercer, Josh Caddy, Cherish Boxall, Kerensa Thorne, Joshua Northey, Louise Stanton, Zoë Konn, Keira Fines, Patrick G. Medd, Adam Coleman, Lorna Nunn, Robert Lown, Pamela McKay, Wendy Osborne, Kim Linton, Graham P. Collins, Andrew J Gentles, Matthew Rose-Zerilli, Gareth Griffiths
Journal: Blood
Blood (2021) 138 (Supplement 1): 715.
https://doi.org/10.1182/blood-2021-148332
Published: 2021
Journal Articles

Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study

Andrew Davies, Josh Caddy, Katy Mercer, Geoff N Saunders, Louise Stanton, Graham P. Collins, MD DPhil, Thomas E C Cummin, MRCP MBBCh BSc, Anna Schuh, MD MRCP, PhD, Kirit M. Ardeshna, Andrew McMillan, John A. Radford, MD FMedSci, David John Lewis, MD, Adam Coleman, Gareth Griffiths, Cathy Burton, MBBChir, MA, MD FRCPath, Sharon Barrans, Peter Johnson, MD FRCP
Journal: Blood
Blood (2020) 136 (Supplement 1): 38–39.
https://doi.org/10.1182/blood-2020-134546
Published: 2020
Journal Articles

Interim Cell-Free Circulating Lymphoma DNA Analysis of the Phase 2 Accept Trial

Anthony Cutts, Edward Wilson, FRCPath, MRCP, Pek Sang Tang, MBBS, Andrew Davies, MD PhD, Peter Johnson, MD FRCP, Louise Stanton, Katy Mercer, Josh Caddy, Anna Schuh, MD MRCP, PhD, Laura Lopez Pascua, PhD, Helene Marie-Pierre Dreau, MSc
Journal: Blood
Blood (2020) 136 (Supplement 1): 24–25.
https://doi.org/10.1182/blood-2020-137439
Published: 2020
Journal Articles

Follicular Lymphoma Frontline Immuno-Chemotherapy: Survival Outcomes and Infection-Related Morbidity

Faouzi Djebbari, Furqaan Kaji, Louise Stanton, Graham P. Collins, MA, MBBS, MRCP, FRCPath, DPhil, Toby A. Eyre
Journal: Blood
Blood (2019) 134 (Supplement_1): 5884.
https://doi.org/10.1182/blood-2019-122213
Published: 2019
Journal Articles

A Prospective Randomised Trial of Targeted Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) Based upon Real-Time Gene Expression Profiling: The Remodl-B Study of the UK NCRI and SAKK Lymphoma Groups (ISRCTN51837425)

Andrew J Davies, MRCP PhD, Josh Caddy, Tom Maishman, Sharon Barrans, PhD, Christoph Mamot, MD, Matthew Care, PhD, Christopher Pocock, Louise Stanton, PhD, Debbie Hamid, Keith Pugh, PhD, Andrew McMillan, PhD, Paul Fields, MDPhD, Anton Kruger, Andrew Jack, PhD MB, Peter W. M. Johnson, FRCP
Journal: Blood
Blood (2015) 126 (23): 812.
https://doi.org/10.1182/blood.V126.23.812.812
Published: 2015
Journal Articles

Real-Time Molecular Classification of Diffuse Large B-Cell Lymphoma (DLBCL) By Gene Expression Profiling (GEP): Successful Delivery of a Routine Service for Randomization of Patients Onto the Multicenter Remodl-B Trial (ISRCTN 51837425)

Barrans Sharon, PhD, Andrew J Davies, MRCP, Ming Wang, Ming-Qing Du, MB, PhD, Christoph Mamot, MD, Keith Pugh, PhD, Josh Caddy, Matthew A Care, PhD, Jan Taylor, Reuben M Tooze, PhD FRCP, Tom Maishman, Louise Stanton, PhD, Debbie Hamid, Andrew McMillan, PhD, Paul Fields, MD PhD, Andrew Jack, PhD MB, Peter Johnson, MD
Journal: Blood
Blood (2015) 126 (23): 331.
https://doi.org/10.1182/blood.V126.23.331.331
Published: 2015